CRI/LinkedIn
Oct 11, 2024, 14:30
How targeting a rare blood cancer complication, or bacteria in colorectal cancer bolster immunotherapy outcomes? – CRI
Cancer Research Institute (CRI) shared on LinkedIn:
“How could targeting a rare blood cancer complication, or bacteria in colorectal cancer bolster immunotherapy outcomes?
CRI Clinical Innovator Dr. Julio Delgado of Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and CRI Postdoctoral Fellow Dr. Jorge Luis Galeano Niño of The University of Texas at El Paso share their insights in our newest blog, during National Hispanic Heritage Month.”
More posts featuring Cancer Research Institute on oncodaily.com
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14